TRANSCRIPT

Q1 2023 — Earnings call remarks

Q1 2023PDF · 10 pages157 KB
Earnings Conference Call
First Quarter 2023 Remarks
April 14, 2023
Moderator:
Good morning, and welcome to the UnitedHealth Group First Quarter 2023 Earnings
Conference Call. A question-and-answer session will follow UnitedHealth Group’s prepared
remarks. As a reminder, this call is being recorded.
Here is some important introductory information. This call contains “forward-looking” statements
under U.S. federal securities laws. These statements are subject to risks and uncertainties that
could cause actual results to differ materially from historical experience or present expectations.
A description of some of the risks and uncertainties can be found in the reports that we file with
the Securities and Exchange Commission, including the cautionary statements included in our
current and periodic filings.
This call will also reference non-GAAP amounts. A reconciliation of the non-GAAP to GAAP
amounts is available on the “Financial & Earnings Reports” section of the Company’s Investor
Relations page at www.unitedhealthgroup.com.
Information presented on this call is contained in the Earnings Release we issued this morning
and in our Form 8-K dated April 14, 2023, which may be accessed from the Investor Relations
page of the Company’s website. I will now turn the conference over to the chief executive officer
of UnitedHealth Group, Andrew Witty.
Andrew Witty
Good morning and thank you all for joining us today.
Growth in the quarter was strong and well-balanced across Optum and
UnitedHealthcare, with revenue increasing 15% to $92 billion. This broad-based growth,
combined with the continued focus of our colleagues on tight execution, helped us
deliver first quarter adjusted earnings per share of $6.26, up 14% over last year.

-- 1 of 10 --

2
• Year to date, UnitedHealthcare increased the number of people served in the U.S.
by 1.2 million, about half of this total within our commercial offerings.
• At Optum Health, we are now serving nearly 700,000 more patients under fully
accountable, value-based arrangements compared to just December 2022.
Given the strength of these results, we are increasing our adjusted earnings per share
outlook for the full year to a range of $24.50 to $25.00 per share.
I know one topic is front of mind for you this morning, so I’ll start with Medicare
Advantage.
With the 2024 Medicare Advantage Notice in hand, we now have greater clarity for the
short- to mid-term evolution of this important program. Our teams are working through
the implications of the changes for 2024 and will be ready to submit bids in just a few
weeks.
While we remain concerned about some of the potential unintended consequences of
the changes of the risk adjustment model — particularly around adequate diagnosis and
support for people with diabetes, complex behavioral needs and more — we do
appreciate CMS’ decision to phase in the changes.
This phase-in will allow for more time to minimize the impacts on beneficiaries as we
lean on the multiple levers available to us … including our ability to manage costs and
our relentless focus on member and patient needs.
We expect the many years of work and investment our teams have put into product and
value differentiation … as well as quality measures, such as Stars scores … will enable
us to continue to offer leading value to Medicare beneficiaries … and to grow strongly
for years to come.

-- 2 of 10 --

3
We are committed to working with CMS as stewards of the MA program, especially with
its long-stated goal of promoting value-based care, which remains the best solution to
promote equitable access, better health care outcomes, exceptional experiences and
lower costs for the system. And importantly, it best supports people who have
historically been underserved and who faced fragmented, less effective care under
traditional fee-for-service.
Seniors know that with MA, versus fee-for-service, they can access a more integrated
and comprehensive suite of critical health benefits — including prescription medicines,
vision, dental and hearing care. They can seek care in more convenient settings … they
experience better health outcomes, such as an over 40% lower rate of avoidable
hospitalizations, and consistently derive much greater value. In fact, the typical
Medicare Advantage senior spends about $2,000 a year less out-of-pocket compared to
seniors in traditional Medicare.
And well over 90% of seniors in Medicare Advantage report they are highly satisfied
with their coverage and care. That’s why more than 30 million Americans — fully half of
all seniors — choose Medicare Advantage today.
Over the past year, we have focused on improving the consumer experience across our
company. This consumer-orientation is foundational in support of each of our growth
priorities, including our approach to value-based care.
For example, this year we expect to serve more than 4 million patients in fully
accountable, value-based care arrangements through Optum, about double where we
were at the end of 2021.
These patients will be members of UnitedHealthcare benefit plans or one of the many
other plans served by Optum. Many of them are in Medicare Advantage … and
increasingly we are serving people with Medicaid or commercial benefits … an
important growth focus for the coming years.

-- 3 of 10 --

4
We’ve spent well more than a decade investing in essential infrastructure and offering
extensive practice transition support to enable tens of thousands of care providers to
participate in this comprehensive, value-based approach.
By integrating traditional ambulatory care with specialty, behavioral and pharmacy care
across in-clinic, virtual and in-home settings — we are delivering measurably better
health outcomes for patients. All while improving access and lowering costs for people
and the health care system overall.
Our focus on consumers is helping to drive growth within Health Benefits, including
strong growth in our commercial offerings. And our early indications are for continued
robust commercial growth in 2024.
From our employee-centered Surest insurance offering … to our innovative financial
services for both members and care providers … to our improved pharmacy home
delivery services and zero copays on lifesaving drugs ... through all of these initiatives
and more, we are firmly on track to put the member, patient and consumer at the very
heart of what we do.
One last note on UnitedHealthcare benefits and the resumption of Medicaid
redeterminations. Now that the process has started, we are working with our state
partners and others to provide as much information and support as possible, so people
can understand and access their best coverage options. And we expect to be serving
more people in our benefit programs when this process is completed.
And now, I’ll turn it over to UnitedHealth Group President and Chief Operating Officer
Dirk McMahon.
Dirk?

-- 4 of 10 --

5
Dirk McMahon
Thanks, Andrew.
Picking up on redeterminations, for many months we have been preparing to help
people when this activity resumes, as it now has in over 20 states. We are working
closely with Medicaid members to navigate eligibility guidelines and help find alternative
coverage options if they are no longer Medicaid-eligible. This effort includes live
outreach calls to educate and assist members with renewal process to ensure they
retain their existing coverage or can transition to other plans.
We are also engaged with employers to extend annual enrollment periods and drive
awareness for employees who are eligible for coverage. With extended eligibility and
increased subsidies, many people will qualify for other plans … some with no monthly
premium. UnitedHealthcare is executing on detailed plans to ensure as many people as
possible have uninterrupted access to coverage and care if they are no longer eligible
for Medicaid.
Let me turn now to the opportunity we have to more deeply and effectively serve people
in their homes.
Nearly all the patients we’ll add this year in fully accountable, value-based relationships
will have access to support through our home-based platform. Consumers value and
benefit from services delivered in the home, and we have expanded our capabilities to
serve that need.
I’ll highlight four of our key capabilities in this important area:
• First, Patient Assessments — In-home clinical visits designed to identify care needs
and help patients with other physical and social needs. This year we expect to make
more than 2.5 million visits to patients’ homes, and we continue to expand the scope
of the clinical services offered in that setting.

-- 5 of 10 --

6
• Next … Care Transitions — This entails supporting patients into and through post-
acute settings ... helping people to avoid hospital re-admissions after an inpatient
stay. This year, we will manage nearly 12 million care transitions, about twice as
many as just three years ago. This plays an important role in helping people return
safely home and in connecting patients with additional in-home support.
• Third area — Senior Community Care — this is clinical care for seniors who live in
skilled nursing and assisted living facilities and dedicated senior housing. Our clinical
teams provide additional layers of care and on-call resources. And they coordinate
among patients and their primary care provider, facility staff and caregivers — all
contributing to strong quality of care and outcomes.
• And the fourth area of clinical capability is individual care and coordination for
Medicare Dual and Chronic Special Needs patients. These patients frequently
require a more individualized approach to care. On average, these patients are
managing nine different chronic conditions, and taking multiple medications. Our
high-touch approach leads to better outcomes, including an over 15% reduction in
hospitalizations, high patient satisfaction with an NPS of nearly 80, with 99% of our
patients in a four star or higher plan.
Our recent combination with LHC Group expands in-home capabilities. LHC provides
high-quality, compassionate home health, hospice and post-acute care services, with
over 12 million patient encounters each year. We will learn from and build upon LHC’s
capabilities, expanding the scope and acuity of the care we can provide in a patient’s
home.
And finally, shifting to pharmacy care services — Optum Rx just completed another
strong growth season. We are winning new relationships by offering the lowest cost and
strong service, across a wide variety of customers — from health plans … to labor and
governments … and to commercial employers. We help customers obtain the best net

-- 6 of 10 --

7
cost and we use our clinical expertise to help treat conditions that call for specialty
medications.
In addition, consumers are benefiting from efforts such as:
• Price Edge, which gives them the best price option whether on or off benefit.
• UnitedHealthcare’s introduction last year of zero-cost lifesaving drugs.
• And our ability to manage the introduction of biosimilars on equal footing with the
existing branded product.
In short: We have consumers’ backs.
With that, let me hand it over to Chief Financial Officer John Rex.
John Rex
Thank you, Dirk.
Fundamental execution has long been an essential aspect of UnitedHealth Group’s
ability to deliver for all those we serve. We know that if we meet or exceed our
commitments and strive to live up to our potential, we will continue to generate high-
quality, durable growth.
Our first quarter performance was highlighted by the strong and accelerating growth
achieved across the businesses of UHC and Optum. We accomplished this while
continuing to expand upon the foundations which will drive the future growth you have
come to expect from us.
Revenue in the first quarter of $92 billion grew by nearly $12 billion or 15% over the
prior year, with double-digit growth at both Optum and UnitedHealthcare. This growth
was achieved by serving more people across all our businesses, and, importantly, by
serving them more comprehensively.

-- 7 of 10 --

8
UnitedHealthcare served about 1.2 million more people in the first three months of the
year … with strong growth across commercial, Medicare and Medicaid. Optum
revenues grew 25% to $54 billion.
Care patterns remain largely consistent with recent trends. For example:
• Inpatient trends continue to reflect the growing, long-term movement towards
ambulatory sites of care. Today, nearly two-thirds of orthopedic procedures are
performed in outpatient and other ambulatory settings, compared to under one-
quarter just five years ago.
• Physician office activity continues to trend toward historic levels, while a few
categories, such as pediatrics, remain lower.
• Emergency room visits remain modestly lower than historical levels, with consumers
seemingly more comfortable with virtual and walk-in care.
• Cancer and cardiac screenings are occurring at roughly pre-pandemic levels, helped
in part by focused efforts to ensure people are obtaining appropriate, preventive
care.
• As always, we continue to closely analyze data for indications which could signal
increasing acuity … but have yet to see those emerge.
Looking now at the performance of the individual businesses in the first quarter:
Optum Health revenues grew by 38% to $23 billion as we expanded the number of
patients served under value-based care arrangements. Revenue per consumer served
grew by 34%, driven by the increase in value-based care patients and in the levels of
care we can offer.

-- 8 of 10 --

9
Optum Insight revenues grew 40% to $4.5 billion. The revenue backlog reached
$30.7 billion, an increase of nearly $8 billion over last year, in part due to the addition of
Change Healthcare. As we have discussed before, in the first half, we expect to
continue to increase our integration and investment activities, which were a component
in the first quarter results … and we expect they will accelerate into the second quarter.
Optum Rx revenues grew 15%, surpassing $27 billion, driven by strong double-digit
growth across the businesses, including in our community and home delivery
pharmacies. Script growth of 26 million over last year was driven by exceptional
customer retention as well as new customer adds. We continue to see strong growth in
NPS for our specialty businesses, up nearly 10 points since last year.
At UnitedHealthcare, revenues of over $70 billion grew 13%, with growth in the number
of people served across all of our major benefit categories.
For example, in commercial, we set out to serve up to 1 million more people this year
and are pacing well to that objective given our first quarter performance. Offerings for
large employers led the gains, as did our newer, and more affordable offerings serving
both employers and individuals.
Within Medicare Advantage, we shared with you in November our intention to add
800,000 to 900,000 new members in this year, and we now expect to exceed the upper
end of that range. The consistent consumer receptivity to our offerings underscores the
product stability and value we provide for seniors.
Medicaid membership grew 570,000 over the year ago quarter. We continue to have
momentum in Medicaid, with recent wins in Indiana and Texas. And we are honored to
advance our existing service to the people of North Carolina, as the state moves toward
expanding managed Medicaid offerings.
Our capital capacities remain strong. Cash flows from operations in the quarter, at

-- 9 of 10 --

10
$16.3 billion, reflected an additional CMS payment. Adjusting for this effect, first quarter
cash flows from operations were consistent with our outlook and we continue to track
well with our full year view to approach $28 billion, about 1.2 times net income.
In the quarter, we returned over $3.5 billion to shareholders through dividends and
share repurchases and deployed about $8 billion of growth capital to expand our
capabilities to serve more people and grow far into the future.
As Andrew mentioned, based upon this growth outlook, today we increased our full year
2023 adjusted earnings outlook to a range of $24.50 to $25.00 per share. We expect
the first half/second half earnings progression to be broadly consistent with our longer-
term historical patterns, with the second half comprising just slightly more than half of
the full year.
Now I’ll turn it back to Andrew.
Andrew Witty
Thanks, John.
Our comments on this call give just a flavor of why we are confident in our outlook for
the year and our long-term, 13% to 16% earnings per share growth target. Our growth is
broad-based and is driven within and increasingly across our businesses, bolstered as
always by an enterprise focus on execution on behalf of those we serve.

-- 10 of 10 --